 |
市場調査レポート
商品コード
1373845
特発性肺線維症 (IPF) 治療薬の世界市場 (2023-2030年)：タイプ (ピルフェニドン・ニンテダニブ)・流通チャネル (病院薬局・小売薬局・オンラインプロバイダー)・別の規模・シェア・成長分析・予測Global Idiopathic Pulmonary Fibrosis Treatment Market Size, Share, Growth Analysis, By Type(Pirfenidone and nintedanib), By Distribution channel(Hospital pharmacies, retail pharmacies and online providers) - Industry Forecast 2023-2030 |
||||||
| 特発性肺線維症 (IPF) 治療薬の世界市場 (2023-2030年)：タイプ (ピルフェニドン・ニンテダニブ)・流通チャネル (病院薬局・小売薬局・オンラインプロバイダー)・別の規模・シェア・成長分析・予測 |
|
出版日: 2023年10月09日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
世界の特発性肺線維症 (IPF) 治療薬の市場規模は、2021年の33億1,000万米ドル、2022年の35億4,000万米ドルから、予測期間中は6.8%のCAGRで推移し、2030年には59億9,000万米ドルの規模に成長すると予測されています。
世界のIPF治療薬の市場は、近年著しい成長と進歩を遂げています。特発性肺線維症は、肺組織の瘢痕化と肥厚を特徴とする慢性かつ進行性の肺疾患であり、呼吸困難と肺機能の低下をもたらします。同市場は、IPFの有病率の増加、高齢者人口の増加、疾患に対する意識の高まりといった要因によって牽引されてきました。さらに、高解像度コンピュータ断層撮影 (HRCT) などの診断技術の進歩や、新規治療法の開発も市場の成長に寄与しています。IPFの治療状況には、ピルフェニドンやニンテダニブなどの薬理学的介入が含まれ、これらは疾患の進行を遅らせるために規制当局から承認されています。さらに、肺移植は、末期IPFの適格な患者に対する実行可能な治療選択肢と考えられています。近年、R&D活動が活発化し、潜在的な治療標的や有望な薬剤候補の出現につながっています。さらに、効果的な治療オプションの開発を加速させるため、製薬企業と研究機関の共同研究や提携が市場で見られるようになっています。
しかし一方で、高額な治療費、新興地域における患者の認知度の低さ、決定的な治療法の欠如といった課題が依然として残されています。
当レポートでは、世界の特発性肺線維症 (IPF) 治療薬の市場を調査し、市場概要、市場への各種影響因子の分析、技術・イノベーションの動向、法規制環境、市場規模の推移・予測、各種区分・地域別の内訳、競合情勢、主要企業のプロファイルなどをまとめています。
目次
- エグゼクティブサマリー
- 調査手法
- 親市場の分析
- 市場概要
- 市場規模
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 主要な市場洞察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- IP分析
- 貿易分析
- スタートアップ分析
- 原材料分析
- イノベーションマトリックス
- パイプライン製品の分析
- マクロ経済指標
- 主要投資分析
- 主要な成功要因
- 競合の程度
- 市場力学と見通し
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 市場力学
- 規制状況
- ポーターの分析
- 将来のディスラプションに関するSkyquestの特別な洞察
- 世界の特発性肺線維症 (IPF) 治療薬市場：タイプ別
- 市場概要
- ピルフェニドン
- ニンテダニブ
- 世界の特発性肺線維症 (IPF) 治療薬市場：流通チャネル別
- 市場概要
- 病院薬局
- 小売薬局・オンラインプロバイダー
- 世界の特発性肺線維症 (IPF) 治療薬市場：地域別
- 市場概要
- 北米
- 欧州
- アジア太平洋
- ラテンアメリカ
- 中東・アフリカ
- 競合情勢
- トップ5社の比較
- 主要企業の市場での位置付け
- 主要企業の採用戦略
- 主要成功戦略
- 市場における最近の活動
- 主要企業の市場シェア
- 主要企業プロファイル
- AstraZeneca PLC
- Bristol-Myers Squibb Company
- Boehringer Ingelheim
- GNI Group Ltd
- F. Hoffmann-La Roche Ltd.
- Shiongi co Ltd
- Mission Therapeutics
- Biogen, Inc.
- Galapagos NV
- FibroGen, Inc.
- GlaxoSmithKline plc
- Genzyme Corporation
- Actelion Pharmaceuticals Ltd
- Promedior, Inc.
- MediciNova, Inc.
- Cipla Limited
- InterMune, Inc.
- Phytopharm plc
- Galecto Biotech AB
- Celtaxsys, Inc.
Global Idiopathic Pulmonary Fibrosis Treatment Market size was valued at USD 3.31 Billion in 2021 and is poised to grow from USD 3.54 Billion in 2022 to USD 5.99 Billion by 2030, at a CAGR of 6.8% during the forecast period (2023-2030).
The Global Idiopathic Pulmonary Fibrosis (IPF) Treatment Market has witnessed significant growth and advancements in recent years. Idiopathic pulmonary fibrosis is a chronic and progressive lung disorder characterized by the scarring and thickening of lung tissues, leading to breathing difficulties and reduced lung function. The market for IPF treatment has been driven by factors such as increasing prevalence of IPF, growing geriatric population, and rising awareness about the disease. Furthermore, advancements in diagnostic techniques, such as high-resolution computed tomography (HRCT), and the development of novel therapies have also contributed to the market growth. The treatment landscape for IPF includes pharmacological interventions, such as pirfenidone and nintedanib, which are approved by regulatory authorities for slowing down disease progression. Additionally, lung transplantation is considered as a viable treatment option for eligible patients with end-stage IPF. In recent years, there has been a surge in research and development activities, leading to the emergence of potential therapeutic targets and promising drug candidates. Moreover, the market is witnessing collaborations and partnerships between pharmaceutical companies and research institutions to accelerate the development of effective treatment options. However, challenges such as high treatment costs, limited patient awareness in developing regions, and the lack of definitive curative therapies still persist. Nevertheless, the global IPF treatment market is expected to continue its growth trajectory, driven by ongoing research, technological advancements, and a growing focus on improving the quality of life for IPF patients.
Top-down and bottom-up approaches were used to estimate and validate the size of the global Emergency Lighting Systems Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Idiopathic Pulmonary Fibrosis Treatment Market Segmental Analysis
The Global Idiopathic Pulmonary Fibrosis Treatment Market is segmented on the basis of type, distribution channel, and region. Based on type, the market can be segmented into Pirfenidone and nintedanib. Based on distribution channel, the market is segmented into Hospital pharmacies, retail pharmacies and online providers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Global Idiopathic Pulmonary Fibrosis Treatment Market Dynamics
Drivers of the Global Idiopathic Pulmonary Fibrosis Treatment Market
Increasing prevalence of IPF
One key driver of the Global Idiopathic Pulmonary Fibrosis (IPF) Treatment Market is the increasing prevalence of IPF. The rising incidence of IPF globally, particularly among the aging population, is driving the demand for effective treatment options. As the number of diagnosed IPF cases continues to grow, there is a greater need for pharmaceutical interventions and therapies that can slow down disease progression and improve patients' quality of life.
Restraints in the Global Idiopathic Pulmonary Fibrosis Treatment Market
High treatment costs
One key restraint of the IPF treatment market is the high treatment costs. The cost of IPF treatment, including medications, diagnostic tests, and supportive care, can be significant and pose a financial burden on patients and healthcare systems. The high cost of treatment may limit access to effective therapies, especially in regions with limited healthcare resources or inadequate insurance coverage. This can result in disparities in treatment availability and affordability, impacting patients' ability to access appropriate care and potentially leading to suboptimal outcomes.
Market Trends of Global Idiopathic Pulmonary Fibrosis Treatment Key
Increasing focus on personalized medicine and precision therapeutics
One key market trend in the Global Idiopathic Pulmonary Fibrosis (IPF) Treatment Market is the increasing focus on personalized medicine and precision therapeutics. With advancements in understanding the underlying mechanisms and heterogeneity of IPF, there is a growing emphasis on tailoring treatment approaches based on individual patient characteristics and disease subtypes. This trend involves the identification of biomarkers, genetic profiling, and the development of targeted therapies that can address specific molecular pathways associated with IPF progression. The aim is to improve treatment outcomes by providing more precise and effective therapies that have the potential to slow down disease progression and improve patients' quality of life.
Table of Contents
- Executive Summary
- Market Overview
- Wheel of Fortune
- Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
- Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
- Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
- Global Idiopathic Pulmonary Fibrosis Treatment Market by Type
- Market Overview
- Pirfenidone and nintedanib
- Global Idiopathic Pulmonary Fibrosis Treatment Market by Distribution channel
- Market Overview
- Hospital pharmacies
- retail pharmacies and online providers
- Global Idiopathic Pulmonary Fibrosis Treatment Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
- Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
- Key Company Profiles
- AstraZeneca PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol-Myers Squibb Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Boehringer Ingelheim (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GNI Group Ltd (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Shiongi co Ltd (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Mission Therapeutics (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biogen, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Galapagos NV (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- FibroGen, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Genzyme Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Actelion Pharmaceuticals Ltd (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Promedior, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- MediciNova, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cipla Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- InterMune, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Phytopharm plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Galecto Biotech AB (Sweden)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Celtaxsys, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
